Mr. James Lee reports

HEALWELL AI PROVIDES CORPORATE UPDATE HIGHLIGHTING PLATFORM INTEGRATION PROGRESS, EMBEDDED AI EXPANSION AND CONTINUED PORTFOLIO SIMPLIFICATION

Healwell AI Inc. has provided a corporate update highlighting continued progress across platform and business integration, including the completion of a major milestone in its integration strategy, AI-enabled (artificial intelligence) product development, and an amplified focus on upsell and cross-sell opportunities through Orion Health's global sales distribution network, as well as continuing work to refine its refocused strategy as a pure play SaaS (software-as-a-service), services and AI business and to pursue opportunities for portfolio simplification.

Integration progress driving commercial momentum

Healwell has made significant progress integrating its AI capabilities and software platforms following its strategic portfolio optimization. The company has successfully integrated its Khure and Pentavere AI capabilities into a unified AI engine powered by Darwen while also integrating its clinical operations and commercial sales teams, driving more robust operational and commercial scale. Building on this progress, Healwell has expanded its offerings across the joint customer base through co-ordinated Orion-Verosource commercial initiatives, which is enabling new upsell and cross-sell opportunities and supporting a robust commercial pipeline entering 2026.

"The integration of our AI platforms has been well received by customers and has translated directly into new opportunities for expanded life science partner agreements," said James Lee, chief executive officer of Healwell AI. "This validates our focused strategy of building cohesive, enterprise-grade AI solutions that deliver real clinical and economic value."

AI-enhanced software platforms gaining market acceptance

Healwell continues to embed AI capabilities directly into its software platforms, creating differentiated, workflow-native solutions for health care customers. Amadeus AI represents the company's next-generation AI-enabled digital care record, with active commercial opportunities across Canada, the United States, Europe and the Middle East.

The integration of Healwell's AI capabilities into Orion Health's infrastructure is showing early commercial traction. These offerings combine Orion Health's more-than-30-year record in health care IT (information technology) with Healwell's clinically validated AI and, coupled with Verosource's data science and analytics capabilities, deliver a broader AI and data science portfolio that is resonating well across Orion Health's customer base.

Healwell's award-winning Darwen AI platform (a Prix Galien award recipient) continues to expand its disease-state coverage and life sciences customer base, with recent advancements in AI-driven label expansion and patient identification capabilities.

The company is also strengthening its validation and credibility in applied health care AI through a growing body of scientific publications, clinical collaborations and expansion into additional disease areas, including complex and neurodegenerative conditions. In the fourth quarter of 2025, Healwell had four publications accepted: one in the Journal of the Canadian Association of Gastroenterology (JCAG), two presented at United European Gastroenterology (UEG), and one presented at the European Crohn's and Colitis Organisation (ECCO).

"Health care IT adoption requires trust, validation and security, particularly in enterprise and public-sector environments," said Dr. Alexander Dobranowski, president of Healwell. "By embedding proven AI into established platforms with long-standing customer relationships, we believe we are uniquely positioned to drive adoption at scale."

Strategic focus and portfolio simplification

Following its refocused strategy, Healwell continues to execute against key integration milestones and unlock synergies to support improved profitability and economies of scale. Building on the divestments announced on Nov. 3, 2025, Healwell is also evaluating opportunities for portfolio simplification. As part of this continuing review, the company is assessing its portfolio of strategic investments, which include a $2-million (U.S.) investment in a dedicated investment vehicle that holds an interest in xAI, as previously announced on June 26, 2024, now part of SpaceX, pursuant to their merger announced on Feb. 2, 2026, as well as a number of smaller investments in private health-care-focused technology companies.

Healwell believes its progress on integration, expanding commercial traction and alignment with structural health care tailwinds position the company well to execute on its long-term strategy to become a global AI and data science partner to life sciences companies, health systems and public-sector organizations.

Mr. Lee commented: "Our strategy is clear: We are building a global carriage network to enable the adoption of AI-assisted preventive care through early disease detection. Unlike many industries, we see AI as an opportunity, not a threat. Our long-standing customers and deep library of peer-reviewed publications -- now numbering over 50 -- are unique. In our opinion, everything about Healwell, including our M&A (merger and acquisition) strategy is deliberately focused on expanding our carriage network and our capabilities while keeping the patients and clinicians outcome at the very core of what we do."

About Healwell AI Inc.

Healwell is a health care artificial intelligence company focused on preventive care. Its mission is to improve health care and save lives through early identification and detection of disease. Using its own proprietary technology, the company is developing and commercializing advanced clinical decision support systems that can help health care providers detect rare and chronic diseases, improve the efficiency of their practice, and ultimately help improve patient health outcomes. Healwell is executing a strategy centred around developing and acquiring technology and clinical sciences capabilities that complement the company's road map. Healwell is publicly traded on the Toronto Stock Exchange under the symbol AIDX and on the OTC (over-the-counter) exchange under the symbol HWAIF.

We seek Safe Harbor.